The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study
Abstract Background Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China. To estimate the survival differences among patients with different stages and va...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-10-01
|
| Series: | Chinese Journal of Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40880-017-0250-3 |
| _version_ | 1819086640618930176 |
|---|---|
| author | Tingting Zuo Hongmei Zeng Huichao Li Shuo Liu Lei Yang Changfa Xia Rongshou Zheng Fei Ma Lifang Liu Ning Wang Lixue Xuan Wanqing Chen |
| author_facet | Tingting Zuo Hongmei Zeng Huichao Li Shuo Liu Lei Yang Changfa Xia Rongshou Zheng Fei Ma Lifang Liu Ning Wang Lixue Xuan Wanqing Chen |
| author_sort | Tingting Zuo |
| collection | DOAJ |
| description | Abstract Background Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China. To estimate the survival differences among patients with different stages and various subtypes of breast cancer, we conducted a hospital-based multi-center study on breast cancer in Beijing, China. Methods All resident patients diagnosed with primary, invasive breast cancer between January 1, 2006 and December 31, 2010 from four selected hospitals in Beijing were included and followed up until December 31, 2015. Hospital-based data of stage at diagnosis, hormone receptor status, and selected clinical characteristics, including body mass index (BMI), menopausal status, histological grade, and histological type, were collected from the medical records of the study subjects. Overall survival (OS) and cancer-specific survival (CSS) were estimated. Cox proportional hazards models were employed to evaluate the associations of stage at diagnosis and molecular subtype with patient survival. Results The 5-year OS and CSS rates for all patients were 89.4% and 90.3%. Survival varied by stage and molecular subtype. The 5-year OS rates for patients with stage I, II, III, and IV diseases were 96.5%, 91.6%, 74.8%, and 40.7%, respectively, and the corresponding estimates of 5-year CSS rates were 97.1%, 92.6%, 75.6%, and 42.7%, respectively. The 5-year OS rates for patients with luminal A, luminal B, HER2, and triple-negative subtypes of breast cancer were 92.6%, 88.4%, 83.6%, and 82.9%, respectively, and the corresponding estimates of 5-year CSS rates were 93.2%, 89.1%, 85.4%, and 83.5%, respectively. Multivariate analysis showed that stage at diagnosis and molecular subtype were important prognostic factors for breast cancer. Conclusions Survival of breast cancer patients varied significantly by stage and molecular subtype. Cancer screening is encouraged for the early detection and early diagnosis of breast cancer. More advanced therapies and health care policies are needed on HER2 and triple-negative subtypes. |
| first_indexed | 2024-12-21T21:23:28Z |
| format | Article |
| id | doaj.art-385e2b20cc614529bcab7fc5ce7595f3 |
| institution | Directory Open Access Journal |
| issn | 1944-446X |
| language | English |
| last_indexed | 2024-12-21T21:23:28Z |
| publishDate | 2017-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Chinese Journal of Cancer |
| spelling | doaj.art-385e2b20cc614529bcab7fc5ce7595f32022-12-21T18:49:50ZengBMCChinese Journal of Cancer1944-446X2017-10-0136111010.1186/s40880-017-0250-3The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center studyTingting Zuo0Hongmei Zeng1Huichao Li2Shuo Liu3Lei Yang4Changfa Xia5Rongshou Zheng6Fei Ma7Lifang Liu8Ning Wang9Lixue Xuan10Wanqing Chen11National Office for Cancer Prevention and Control & National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Office for Cancer Prevention and Control & National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeKey Laboratory of Carcinogenesis and Translation Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translation Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & InstituteKey Laboratory of Carcinogenesis and Translation Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & InstituteNational Office for Cancer Prevention and Control & National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Office for Cancer Prevention and Control & National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Statistics, The European Organization for Research and Treatment of Cancer (EORTC)Key Laboratory of Carcinogenesis and Translation Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & InstituteDepartment of Breast Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Office for Cancer Prevention and Control & National Central Cancer Registry, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China. To estimate the survival differences among patients with different stages and various subtypes of breast cancer, we conducted a hospital-based multi-center study on breast cancer in Beijing, China. Methods All resident patients diagnosed with primary, invasive breast cancer between January 1, 2006 and December 31, 2010 from four selected hospitals in Beijing were included and followed up until December 31, 2015. Hospital-based data of stage at diagnosis, hormone receptor status, and selected clinical characteristics, including body mass index (BMI), menopausal status, histological grade, and histological type, were collected from the medical records of the study subjects. Overall survival (OS) and cancer-specific survival (CSS) were estimated. Cox proportional hazards models were employed to evaluate the associations of stage at diagnosis and molecular subtype with patient survival. Results The 5-year OS and CSS rates for all patients were 89.4% and 90.3%. Survival varied by stage and molecular subtype. The 5-year OS rates for patients with stage I, II, III, and IV diseases were 96.5%, 91.6%, 74.8%, and 40.7%, respectively, and the corresponding estimates of 5-year CSS rates were 97.1%, 92.6%, 75.6%, and 42.7%, respectively. The 5-year OS rates for patients with luminal A, luminal B, HER2, and triple-negative subtypes of breast cancer were 92.6%, 88.4%, 83.6%, and 82.9%, respectively, and the corresponding estimates of 5-year CSS rates were 93.2%, 89.1%, 85.4%, and 83.5%, respectively. Multivariate analysis showed that stage at diagnosis and molecular subtype were important prognostic factors for breast cancer. Conclusions Survival of breast cancer patients varied significantly by stage and molecular subtype. Cancer screening is encouraged for the early detection and early diagnosis of breast cancer. More advanced therapies and health care policies are needed on HER2 and triple-negative subtypes.http://link.springer.com/article/10.1186/s40880-017-0250-3Breast cancerStageMolecular subtypeSurvivalChina |
| spellingShingle | Tingting Zuo Hongmei Zeng Huichao Li Shuo Liu Lei Yang Changfa Xia Rongshou Zheng Fei Ma Lifang Liu Ning Wang Lixue Xuan Wanqing Chen The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study Chinese Journal of Cancer Breast cancer Stage Molecular subtype Survival China |
| title | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study |
| title_full | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study |
| title_fullStr | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study |
| title_full_unstemmed | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study |
| title_short | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study |
| title_sort | influence of stage at diagnosis and molecular subtype on breast cancer patient survival a hospital based multi center study |
| topic | Breast cancer Stage Molecular subtype Survival China |
| url | http://link.springer.com/article/10.1186/s40880-017-0250-3 |
| work_keys_str_mv | AT tingtingzuo theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT hongmeizeng theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT huichaoli theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT shuoliu theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT leiyang theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT changfaxia theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT rongshouzheng theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT feima theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT lifangliu theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT ningwang theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT lixuexuan theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT wanqingchen theinfluenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT tingtingzuo influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT hongmeizeng influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT huichaoli influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT shuoliu influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT leiyang influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT changfaxia influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT rongshouzheng influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT feima influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT lifangliu influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT ningwang influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT lixuexuan influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy AT wanqingchen influenceofstageatdiagnosisandmolecularsubtypeonbreastcancerpatientsurvivalahospitalbasedmulticenterstudy |